Search
Taurochenodeoxycholic acid
go.drugbank.com/drugs/DB08833ExperimentalTaurochenodeoxycholic acid is an experimental drug that is normally produced in the liver. Its physiologic function is to emulsify lipids such as cholesterol in the bile. As a medication, taurochenodeoxycholic acid reduces cholesterol fo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAgmatine
go.drugbank.com/drugs/DB08838ExperimentalAgmantine is a natural metabolite of the amino acid arginine. It is formed when arginine is decarboxylated by the enzyme arginine decarboxylase and is found naturally in ragweed pollen, ergot fungi, octopus muscle, herring sperm, sponges...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTeriflunomide
go.drugbank.com/drugs/DB08880ApprovedInvestigationalTeriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specific...
Synonyms: (Z)-2-cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-p-crotonotoluidideCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated b...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigationalEnzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 20...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesFormestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnFormestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. Formestane suppresses estrogen production from anabolic steroids or pro...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersFluticasone furoate
go.drugbank.com/drugs/DB08906ApprovedInvestigationalFluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label] . Fluticasone furoate was first approved in 2007 .
Categories: P-glycoprotein inducers, P-glycoprotein substratesIndenolol
go.drugbank.com/drugs/DB08952ApprovedWithdrawnIndenolol is a drug of the beta-adrenergic blocker class.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesFendiline
go.drugbank.com/drugs/DB08980ApprovedWithdrawnFendiline is a coronary vasodilator which inhibits calcium function in muscle cells in excitation-contraction coupling. It has been proposed as an antiarrhythmic and antianginal agent. Fendiline is non-selective.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIbrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIbrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibruti...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates